Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Combination of Low-dose Rituximab and All-trans Retinoic Acid as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial

NCT03304288 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03304288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03304288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Combination of Low-dose Rituximab and All-trans Retinoic Acid as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 11, 2017
Completion date
February 28, 2021
Enrollment
168 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia